Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
Rana R. McKay(University of San Diego), M-E Taplin(Dana-Farber Cancer Institute), Kaitlyn Melnick(UF Health Shands Hospital), Lillian Werner(Dana-Farber Cancer Institute), Olga Voznesensky(Beth Israel Deaconess Medical Center), Katherine Zukotynski(McMaster University), Xin Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Philip W. Kantoff(Dana-Farber Brigham Cancer Center), Steven P. Balk(Beth Israel Deaconess Medical Center), Jifeng Wu(Beth Israel Deaconess Medical Center), Zhiyong Jiang(Guangzhou Medical University), Bruce Montgomery(Immunovaccine (Canada)), Stephen Smith(University of Washington)
Cited by 37
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k